ENDRA Life Sciences Inc. (NDRA)
USD 6.15
(-14.65%)
USD 6.15
(-14.65%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.62 Million USD | -0.83% |
| 2022 | 2.64 Million USD | 105.88% |
| 2021 | 1.28 Million USD | 117.87% |
| 2020 | 589.62 Thousand USD | 419.75% |
| 2019 | 113.44 Thousand USD | 90.84% |
| 2018 | 59.44 Thousand USD | -68.99% |
| 2017 | 191.68 Thousand USD | 377.95% |
| 2016 | 40.1 Thousand USD | -59.49% |
| 2015 | 99 Thousand USD | -58.57% |
| 2014 | 238.98 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 2.71 Million USD | -100.0% |
| 2024 Q1 | 2.71 Million USD | 3.4% |
| 2023 Q3 | 2.75 Million USD | 0.0% |
| 2023 FY | 2.62 Million USD | -0.83% |
| 2023 Q4 | 2.62 Million USD | -4.89% |
| 2023 Q2 | 2.75 Million USD | 0.81% |
| 2023 Q1 | 2.73 Million USD | 3.43% |
| 2022 Q3 | 2.63 Million USD | 10.92% |
| 2022 FY | 2.64 Million USD | 105.88% |
| 2022 Q4 | 2.64 Million USD | 0.4% |
| 2022 Q2 | 2.37 Million USD | 23.03% |
| 2022 Q1 | 1.93 Million USD | 50.26% |
| 2021 Q2 | 1.32 Million USD | 82.33% |
| 2021 Q1 | 726.6 Thousand USD | 23.23% |
| 2021 Q4 | 1.28 Million USD | -14.35% |
| 2021 FY | 1.28 Million USD | 117.87% |
| 2021 Q3 | 1.49 Million USD | 13.21% |
| 2020 Q4 | 589.62 Thousand USD | 82.43% |
| 2020 Q2 | 340.68 Thousand USD | 94.75% |
| 2020 Q1 | 174.93 Thousand USD | 54.21% |
| 2020 FY | 589.62 Thousand USD | 419.75% |
| 2020 Q3 | 323.2 Thousand USD | -5.13% |
| 2019 Q4 | 113.44 Thousand USD | -11.26% |
| 2019 Q3 | 127.83 Thousand USD | 72.09% |
| 2019 Q2 | 74.28 Thousand USD | 0.01% |
| 2019 Q1 | 74.27 Thousand USD | 24.95% |
| 2019 FY | 113.44 Thousand USD | 90.84% |
| 2018 Q1 | 245.96 Thousand USD | 28.32% |
| 2018 Q4 | 59.44 Thousand USD | -81.88% |
| 2018 Q2 | 279.21 Thousand USD | 13.52% |
| 2018 Q3 | 328.04 Thousand USD | 17.49% |
| 2018 FY | 59.44 Thousand USD | -68.99% |
| 2017 Q3 | 131.67 Thousand USD | -1.31% |
| 2017 Q1 | 40.23 Thousand USD | 0.33% |
| 2017 FY | 191.68 Thousand USD | 377.95% |
| 2017 Q4 | 191.68 Thousand USD | 45.57% |
| 2017 Q2 | 133.42 Thousand USD | 231.59% |
| 2016 Q2 | 21.37 Thousand USD | 0.0% |
| 2016 FY | 40.1 Thousand USD | -59.49% |
| 2016 Q4 | 40.1 Thousand USD | -85.51% |
| 2016 Q3 | 276.85 Thousand USD | 1195.23% |
| 2016 Q1 | - USD | -100.0% |
| 2015 Q4 | 99 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 99 Thousand USD | -58.57% |
| 2014 FY | 238.98 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Biodesix, Inc. | 1.4 Million USD | -87.348% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -14089.921% |
| Castle Biosciences, Inc. | 7.94 Million USD | 66.975% |
| DarioHealth Corp. | 5.06 Million USD | 48.185% |
| Exact Sciences Corporation | 127.47 Million USD | 97.942% |
| IDEXX Laboratories, Inc. | 380.28 Million USD | 99.31% |
| Illumina, Inc. | 587 Million USD | 99.553% |
| Intelligent Bio Solutions Inc. | 777.53 Thousand USD | -237.33% |
| iSpecimen Inc. | - USD | -Infinity% |
| Standard BioTools Inc. | 20.53 Million USD | 87.226% |
| 23andMe Holding Co. | 12.46 Million USD | 78.958% |
| Medpace Holdings, Inc. | 1.00 USD | -262286400.0% |
| NeoGenomics, Inc. | 24.15 Million USD | 89.142% |
| Inotiv, Inc. | 56.1 Million USD | 95.325% |
| Psychemedics Corporation | 1.00 USD | -262286400.0% |
| Prenetics Global Limited | 3.12 Million USD | 16.116% |
| Precipio, Inc. | 384 Thousand USD | -583.038% |
| RadNet, Inc. | 1.00 USD | -262286400.0% |
| Sotera Health Company | 51.98 Million USD | 94.955% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 23.308% |
| Exagen Inc. | 2.87 Million USD | 8.643% |
| Natera, Inc. | 40.75 Million USD | 93.565% |
| Aspira Women's Health Inc. | 227 Thousand USD | -1055.447% |
| Neogen Corporation | 189.26 Million USD | 98.614% |
| Myriad Genetics, Inc. | 20.1 Million USD | 86.951% |
| ICON Public Limited Company | 1.00 USD | -262286400.0% |
| Bionano Genomics, Inc. | 22.89 Million USD | 88.543% |
| CareDx, Inc | 19.47 Million USD | 86.529% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 32.06 Million USD | 91.82% |
| Guardant Health, Inc. | 61.94 Million USD | 95.766% |
| BioNexus Gene Lab Corp. | 1.13 Million USD | -130.527% |
| Fulgent Genetics, Inc. | 5.82 Million USD | 54.988% |
| Sera Prognostics, Inc. | - USD | -Infinity% |
| OPKO Health, Inc. | 65.69 Million USD | 96.008% |
| Personalis, Inc. | 5.66 Million USD | 53.668% |
| Applied DNA Sciences, Inc. | 330.02 Thousand USD | -694.743% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 23.308% |
| MDxHealth SA | 2.77 Million USD | 5.618% |
| Prenetics Global Limited | 3.12 Million USD | 16.116% |
| Mainz Biomed B.V. | 613.63 Thousand USD | -327.429% |
| Trinity Biotech plc | 19.93 Million USD | 86.842% |
| Neuronetics, Inc. | 8.09 Million USD | 67.591% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -14089.921% |